PLAT and COVID-19: In addition, the administration of tPA systemically was linked to a decrease in mortality [47.6% (tPA) vs. 71.0% (no tPA)] for COVID-19 patients who had a refractory PaO2/FiO2 of less than 60 mmHg (135).